Gabrelli Health & Wellness Trust

Bank of America Raises Johnson & Johnson's Target Price to $220

Merck Expects Mid-Single-Digit Revenue Growth in FY 2026

US FDA Grants Priority Review Voucher to Johnson & Johnson for Blood Cancer Treatment

Fitch Confirms Cencora's Stable Outlook, Acquires OneOncology

Cencora Acquires Controlling Stake in OneOncology

Johnson & Johnson's Prostate Cancer Therapy Akeega Receives FDA Approval

U.S. Trust Increases Holdings in AbbVie Inc.

Thrivent Financial for Lutherans Increased Merck Holdings in Q2

North Dallas Bank & Trust Invests $919,000 in Merck in Q2

Wells Fargo Raises Johnson & Johnson's Price Target to $230

LM Advisors LLC Reduces Holdings in Merck

Ampergy Financial Increased Holdings in Merck & Co., Inc., Executive Reduced

Wall Street Zen Downgrades Teva Pharmaceutical to Buy

Johnson & Johnson's AKEEGA® Approved by FDA for BRCA2 Mutated Prostate Cancer

Teva to Release Q4 2025 Financial Results

Morgan Stanley Raises Merck's Target Price to $102

Merck Receives Positive CHMP Recommendation to Expand WINREVAIR Use

Diversify Advisory Services LLC Increased Holdings in AbbVie Inc.

Teva Extends $2.5 Billion Revolving Credit Facility and Amends Financial Covenants

Teva Pharmaceutical Insiders Sold $3,311,126 in Shares

Radiopharm Theranostics

AMC Robotics

Artiva Biotherapeutics

3 E Network Tech

Kaixin

Ascent Solar Tech

Quipt Home Medical

Maase 

Netclass Tech

Climb Bio

ABBV

AbbVie’s (ABBV) Options Flow Implies That the Smart Money Could Be Up to Something

Barchart Option

Abbvie

AbbVie’s (ABBV) Options Flow Implies That the Smart Money Could Be Up to Something

MarketBeat's stock screener tool identifies Eli Lilly, Pfizer, and AbbVie as promising pharmaceutical stocks to watch. These companies offer potential high growth from successful drug pipelines but carry risks like regulatory decisions and clinical-trial outcomes. Eli Lilly has a Moderate Buy rating, but top analysts suggest other stocks may be better buys. Pfizer is investing in weight loss drugs, and AbbVie offers treatments for various diseases.

- Pfizer, Eli Lilly, and AbbVie are highlighted as key pharmaceutical stocks to monitor due to their significant trading volumes.  
- These companies are involved in the research and development of various drugs, including treatments for diabetes and obesity, and face risks such as regulatory decisions and clinical trial outcomes.  
- The article emphasizes the potential for high growth in pharmaceutical stocks while also noting the inherent volatility associated with the industry.

Market Beat

Eli Lilly

Pfizer

Promising Pharmaceutical Stocks To Watch Now - December 15th

BofA raised Johnson & Johnson's price target to $220, citing steady growth, but sees limited upside from its pipeline through 2026. The FDA awarded a national priority voucher to J&J's Tecvayli for multiple myeloma. Despite positive trial results, BofA's Jason Gerberry notes limited pipeline catalysts and modest impact from upcoming launches, with key data expected in 2026. Investors may focus on Milvexian Phase 3 data in late 2026.

benzinga_article

Johnson & Johnson

Johnson & Johnson Gets Target Hike, But BofA Flags Modest Pipeline Impact

Johnson & Johnson's Akeega has received FDA approval for label expansion in BRCA2-mutated metastatic castration-sensitive prostate cancer (mCSPC). This approval, based on the Phase III AMPLITUDE study, marks Akeega as the first FDA-approved precision medicine combination treatment for BRCA2-mutated mCSPC, potentially changing the standard of care. Akeega, a combination of GSK’s Zejula and J&J’s Zytiga, previously approved for mCRPC, enhances J&J's presence in the competitive prostate cancer market.

Pharmaceutical Technology

J&J gains label expansion approval for Akeega in mCSPC

Financial giants show bearish sentiment on Merck & Co, with 41% of traders bearish and 35% bullish. Analysts from Scotiabank, B of A Securities, Goldman Sachs, Wells Fargo, and Morgan Stanley have issued ratings, with target prices ranging from $102 to $125. Merck's trading volume is 5,509,858, with a price of $99.7, down 0.6%. RSI indicators suggest the stock may be overbought. Earnings announcement expected in 50 days. Benzinga Edge highlights unusual options activity, offering insights into market movers.

Merck

Merck & Co's Options: A Look at What the Big Money is Thinking

Johnson & Johnson Remains Stable With Modest Growth Potential, BofA Says

marketscreener

Johnson & Johnson Remains Stable With Modest Growth Potential, BofA Says

AbbVie's Upside Potential Limited in Pipeline-Light 2026, BofA Securities Says

AbbVie's Upside Potential Limited in Pipeline-Light 2026, BofA Securities Says

BofA Securities expects Merck to achieve mid-single-digit revenue growth in fiscal 2026, driven by Keytruda and Winrevair, despite challenges from Bridion and Januvia. Earnings per share growth is projected to be high-single-digit, excluding M&A dilution. Keytruda QLEX launch is crucial for future growth. Winrevair and Ohtuvayre are key growth drivers. BofA raised Merck's price target to $120, maintaining a buy rating.

fidelity

Merck Poised for Mid-Single-Digit Revenue Growth in Fiscal 2026, BofA Says

The U.S. FDA has granted a national priority voucher to Johnson & Johnson's blood cancer treatment, Tecvayli in combination with Darzalex, for its significant improvement in treating multiple myeloma. This voucher, part of the FDA's National Priority Voucher program, reduces the drug review timeline to 1-2 months. This marks the 16th product to receive such an award this year, highlighting its critical public health importance.

Reuters

US FDA grants priority voucher to J&J's blood cancer treatment

Fitch Ratings has affirmed Cencora, Inc's 'A-' Long-Term and 'F1' Short-Term Issuer Default Ratings with a Stable Outlook. This follows Cencora's announcement to purchase the remaining interest in OneOncology for $5 billion. Fitch expects leverage to increase post-deal but return to target levels within two years. Cencora plans to reduce debt by $3.9 billion by 2028, supported by strong FCF and strategic M&A. The company's stable operations and solid liquidity position underpin its credit profile, despite challenges like opioid litigation and customer concentration risks.

Cencora

Fitch Affirms Cencora's 'A-'/'F1' Ratings; Outlook Stable

Cencora Inc. agrees to acquire a majority stake in OneOncology for $5 billion, pausing stock buybacks. The acquisition is expected to be neutral to EPS in the first year. Cencora reiterates fiscal 2026 guidance, expecting sales growth of 5%-7% and adjusted EPS towards the lower half of $17.45-$17.75. Long-term guidance for operating income and EPS is raised. Cencora shares slightly up in premarket trading.

Cencora Strikes $5 Billion OneOncology Deal, Pauses Stock Buyback

Cencora, Inc. has finalized an agreement to acquire TPG's equity interest in OneOncology, a national platform for independent oncology practices. This acquisition aims to enhance specialty care and support independent physician practices, leveraging Cencora's expertise in healthcare. The partnership seeks to accelerate growth, clinical innovation, and technology capabilities, improving patient access to high-quality care. OneOncology, founded by community physicians, supports 36 partner practices with over 2,300 providers nationwide. Cencora is a global pharmaceutical solutions leader, while TPG is a major asset management firm.

prnewswire

07:26 ET
			
			
				Cencora Finalizes Agreement to Acquire TPG's Equity Interest in OneOncology

Cencora is acquiring a majority stake in OneOncology, valued at $7.4 billion, for $3.6 billion plus $1.3 billion in debt retirement. The deal, expected to close by fiscal 2026 Q2, will be funded through new debt financing. Cencora has paused share repurchases and expects EPS to be at the lower end of its fiscal 2026 guidance.

Cencora Accelerates Acquisition of Majority Stake in OneOncology

Johnson & Johnson announced FDA approval for its prostate cancer therapy, Akeega plus prednisone, targeting metastatic castration-sensitive prostate cancer with BRCA mutation. The approval follows a phase 3 study showing a 54% reduction in radiographic progression or death risk and a 59% delay in symptomatic progression. The safety profile aligns with other FDA-approved therapies.

Johnson & Johnson's Prostate Cancer Therapy Application Approved by US FDA

Johnson & Johnson was hit with a $40 million verdict by the Los Angeles Superior Court over talc-based baby powder allegedly causing ovarian cancer. The award covers compensatory damages for plaintiffs Monica Kent and Deborah Schultz and Schultz's husband. The verdict followed a four-week trial with testimony from former FDA commissioner David Kessler. More trials are expected through H1 2026. Johnson & Johnson did not immediately respond to requests for comment.